Results
Haemonetics Corporation
03/03/2026 | Press release | Distributed by Public on 03/03/2026 05:09
Regulation FD Disclosure (Form 8-K)
Item 7.01 Regulation FD Disclosure.
On March 2, 2026, Haemonetics Corporation (the "Company") repaid in full at maturity its outstanding 0.00% Convertible Senior Notes due 2026 (the "Notes"). The Company paid an aggregate amount of $300,000,000 in cash, representing the outstanding principal amount of the Notes. The repayment was funded with cash on hand and borrowings under the Company's revolving credit facility. No holders exercised conversion rights with respect to the Notes prior to the close of business on the second scheduled trading day immediately preceding the maturity date. The capped call transactions entered into in connection with the issuance of the Notes expired in accordance with their terms upon the maturity of the Notes.
The information in this Item 7.01 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.
Haemonetics Corporation published this content on March 03, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 03, 2026 at 11:09 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]